Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers.

@article{Richards2011MethylationOT,
  title={Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers.},
  author={Kristy L Richards and Baili Zhang and Meng-hong Sun and Wenli Dong and Jennifer D. Churchill and Linda L. Bachinski and Charmaine D. Wilson and Keith A. Baggerly and Guosheng Yin and D. Neil Hayes and Ignacio Wistuba and Ralf Krahe},
  journal={Cancer},
  year={2011},
  volume={117 3},
  pages={606-17}
}
BACKGROUND The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and head and neck cancers. Because of its reported high frequency of hypermethylation in lung cancer, further characterization of the stages and types of nonsmall cell lung cancer (NSCLC) that are hypermethylated and the frequency of hypermethylation and associated "second hits" were assessed. METHODS TCF21 promoter hypermethylation in 105… CONTINUE READING